NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New gene therapy combo offers hope for tough bladder cancer
Disease control Recruiting nowThis study tests a gene therapy (nadofaragene firadenovec) given directly into the bladder, alone or with chemotherapy or immunotherapy, for people with a high-grade bladder cancer that has not responded to standard BCG therapy. The goal is to see if the treatment can make the ca…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:58 UTC
-
New hope for bladder cancer patients: EG-70 trial targets tough cases
Disease control Recruiting nowThis study tests a new drug, EG-70, given directly into the bladder for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). It includes patients whose cancer did not respond to standard BCG therapy, as well as those who haven't had enough BCG treatment. Th…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated May 26, 2026 10:51 UTC